Improved Field of View with Bromocriptine in Prolactinoma
Authors
Abstract:
This article doesn't have abstract
similar resources
Prolactinoma during pregnancy causing compression symptoms responding to bromocriptine therapy.
A woman with pituitary macroadenoma causing pressure symptoms and a partial right third cranial nerve palsy during pregnancy is described. Complete resolution occurred using oral bromocriptine therapy alone and the remainder of the pregnancy was uneventful.
full textPlasma Leptin Levels Before and After Bromocriptine Treatment in Female Patients with Prolactinoma
Both It is known that increased body weight is associated with prolactinomas. However, effects of bromocriptine treatment on plasma leptin levels is not clear yet. The aim of this is to evaluate leptin levels before and after bromocripine treatment in patients with prolactinoma. Twenty female patients with prolactinoma and twenty normoprolactinemic, ageand body mass index (BMI)matched healthy f...
full textInhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells
PURPOSE Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma progression. On the other hand, it is not always effective in clinical application. Although a dopamine D2 receptor deficiency contributes to the impaired efficiency of...
full textInvestigation of the Spatial Resolution and Field of View with Change of Magnification in VRX CT
Introduction: Variable resolution x-ray (VRX) CT is a new type of CT that can image objects at various spatial resolutions. In a VRX CT scanner, the spatial resolution increases at the cost of reduction in the field of view (FOV). An important factor that limits the spatial resolution of the VRX CT is the effect of focal spot size. Also, the optimum magnification is different at each incident a...
full textBromocriptine for visual field defects in prolactinomas.
The introduction of bromocriptine (2-brocergocryptine mesylate), a semi-synthetic ergot alkaloid, has revolutionised the treatment of the amenorrhoeagalactorrhoea syndrome due to excessive prolactin secretion (Thorner et. al., 1975). In a significant number of cases, this hyperprolactinaemia is caused by a radiologically obvious pituitary tumour (L'Hermite et. al., 1977; Bergh et al., 1978 a) w...
full textBromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
OBJECTIVE The objective of this study was to describe and characterize the clinical course of treatment for invasive prolactinoma patients using bromocriptine. METHODS The study group included 23 patients who were treated with bromocriptine for their invasive prolactinomas. Clinical histories, serum prolactin level and pituitary hormone assessments, tumor diameter and signal intensity on sell...
full textMy Resources
Journal title
volume 9 issue 4
pages 206- 210
publication date 1986-03
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023